Medicare beneficiaries seeking access to GLP-1 receptor agonists for weight loss currently face a significant coverage gap, as the Social Security Act prohibits Medicare from covering drugs prescribed solely for weight management. While the "Medicare GLP-1 Bridge" program is not an official federal policy, several private initiatives and health systems have launched temporary bridge programs to help patients transition between insurance coverage or maintain access to medications like semaglutide (Wegovy) and tirzepatide (Zepbound) when they are prescribed for comorbid conditions like Type 2 diabetes or cardiovascular disease.
Current Medicare Coverage Restrictions on Weight Loss Drugs
Under current law, Medicare Part D plans are explicitly barred from covering medications specifically for weight loss. According to the Centers for Medicare & Medicaid Services (CMS), Part D drug coverage excludes agents used for anorexia, weight loss, or weight gain.
However, this exclusion does not apply if the medication is FDA-approved and prescribed for a medically accepted indication other than weight loss. For instance, semaglutide is marketed as Ozempic for the treatment of Type 2 diabetes and as Wegovy for chronic weight management. Medicare covers Ozempic because it is prescribed for diabetes management, but it will not cover Wegovy even if a physician determines it is medically necessary for a patient’s health.
Understanding the Role of Bridge Programs
Because of the high out-of-pocket costs for GLP-1 medications—often exceeding $1,000 per month without insurance—various "bridge" initiatives have emerged. These are generally not government-funded; rather, they are programs facilitated by pharmaceutical manufacturers or independent clinics to assist patients who lose coverage or are transitioning between plans.
- Manufacturer Assistance: Companies like Novo Nordisk and Eli Lilly offer savings cards that can reduce costs for commercially insured patients. These programs generally do not apply to Medicare beneficiaries due to federal anti-kickback statutes, which prevent manufacturers from subsidizing costs for government-insured patients.
- Clinical Transitions: Some integrated health systems have created internal workflows to help patients who were on GLP-1 therapy for diabetes maintain that therapy if their clinical status changes, ensuring continuity of care.
Legislative Efforts to Expand Coverage
There is ongoing debate in Congress regarding the Treat and Reduce Obesity Act (TROA), which seeks to amend the Social Security Act to allow Medicare to cover anti-obesity medications. Supporters argue that the long-term cost of treating obesity-related conditions—such as heart disease, hypertension, and sleep apnea—far outweighs the cost of the drugs. According to a Congressional Budget Office (CBO) analysis, expanding coverage for these drugs would significantly increase federal spending, which has served as a primary hurdle for the bill’s passage.
Frequently Asked Questions
Does Medicare cover Wegovy or Zepbound?
No. Medicare Part D is legally prohibited from covering drugs for weight loss, including Wegovy and Zepbound.
Can I use a manufacturer savings card with Medicare?
No. Federal law prohibits the use of manufacturer copay assistance cards for patients enrolled in government healthcare programs like Medicare and Medicaid.
Is there any way for Medicare to cover a GLP-1 drug?
Medicare may cover a GLP-1 drug only if it is prescribed for an FDA-approved indication other than weight loss, such as Type 2 diabetes or, in the case of Wegovy, to reduce the risk of cardiovascular death, heart attack, and stroke in adults with established cardiovascular disease and either overweight or obesity, as approved by the FDA.
What should patients do if they cannot afford their medication?
Patients are encouraged to discuss lower-cost alternatives or therapeutic equivalents with their healthcare provider. Additionally, patients can check if they qualify for Extra Help, a Medicare program that helps people with limited income and resources pay for Part D premiums, deductibles, and coinsurance.
Related reading